Stephen L. Rawlings

Array ( [id] => 15785321 [patent_doc_number] => 10626371 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => Co-differentiation of monocytes from allogeneic donors [patent_app_type] => utility [patent_app_number] => 15/623530 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 42 [patent_no_of_words] => 9534 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15623530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15397843 [patent_doc_number] => 10539576 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-21 [patent_title] => Lung cancer differential marker [patent_app_type] => utility [patent_app_number] => 15/620214 [patent_app_country] => US [patent_app_date] => 2017-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 15242 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15620214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971178 [patent_doc_number] => 20170275332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS' [patent_app_type] => utility [patent_app_number] => 15/617008 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 33443 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 28 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15617008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12681043 [patent_doc_number] => 20180118847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => MODIFIELD ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/615631 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 81181 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15615631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14960637 [patent_doc_number] => 20190307796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1ALPHA) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) [patent_app_type] => utility [patent_app_number] => 16/303828 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16898980 [patent_doc_number] => 20210177896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELLS [patent_app_type] => utility [patent_app_number] => 16/305728 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 127547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16359368 [patent_doc_number] => 20200316119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => CMV EPITOPES [patent_app_type] => utility [patent_app_number] => 16/303677 [patent_app_country] => US [patent_app_date] => 2017-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058651 [patent_doc_number] => 20170334995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'ANTIBODY MOLECULES FOR CANCER TREATMENT' [patent_app_type] => utility [patent_app_number] => 15/598356 [patent_app_country] => US [patent_app_date] => 2017-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 29998 [patent_no_of_claims] => 75 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15598356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12588873 [patent_doc_number] => 20180088120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => Elevated PSMA Identifies Lethal Prostate Cancers [patent_app_type] => utility [patent_app_number] => 15/595533 [patent_app_country] => US [patent_app_date] => 2017-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15595533 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11914304 [patent_doc_number] => 09782478 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-10-10 [patent_title] => 'Prostate-specific membrane antigen binding proteins and related compositions and methods' [patent_app_type] => utility [patent_app_number] => 15/585921 [patent_app_country] => US [patent_app_date] => 2017-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 12 [patent_no_of_words] => 38217 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15585921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11888031 [patent_doc_number] => 09758583 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-12 [patent_title] => 'Anti-CTLA-4 antibodies' [patent_app_type] => utility [patent_app_number] => 15/486468 [patent_app_country] => US [patent_app_date] => 2017-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 23 [patent_no_of_words] => 26013 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15486468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001895 [patent_doc_number] => 20170306050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES' [patent_app_type] => utility [patent_app_number] => 15/482452 [patent_app_country] => US [patent_app_date] => 2017-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 42861 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15482452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312643 [patent_doc_number] => 20200291381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => PRODUCTION OF ANTIGEN-SPECIFIC T-CELLS [patent_app_type] => utility [patent_app_number] => 16/084121 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11873625 [patent_doc_number] => 09745382 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-08-29 [patent_title] => 'Bispecific anti-HER2 antibody' [patent_app_type] => utility [patent_app_number] => 15/461732 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 21 [patent_no_of_words] => 13365 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15461732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12151538 [patent_doc_number] => 20180022802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/451268 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 33807 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706262 [patent_doc_number] => 20170174761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/451280 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 33780 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001857 [patent_doc_number] => 20170306012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/451275 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 33788 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13251215 [patent_doc_number] => 10138287 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-27 [patent_title] => Uterine cancer treatments [patent_app_type] => utility [patent_app_number] => 15/451167 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 18 [patent_no_of_words] => 34459 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001856 [patent_doc_number] => 20170306011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/451253 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 33803 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15193925 [patent_doc_number] => 10494441 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-03 [patent_title] => Anti-ERBB3 antibodies [patent_app_type] => utility [patent_app_number] => 15/448164 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 30 [patent_no_of_words] => 24949 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15448164 [rel_patent_id] =>[rel_patent_doc_number] =>)